[EN] 3-SUBSTITUTED-1H-INDOLE, 3-SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE AND 3-SUBSTITUTED-1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES<br/>[FR] COMPOSÉS 1H-INDOLE SUBSTITUÉ EN POSITION 3, 1H-PYRROLO[2,3-B]PYRIDINE SUBSTITUÉE EN POSITION 3 ET 1H-PYRROLO[3,2-B]PYRIDINE SUBSTITUÉE EN POSITION 3, LEUR UTILISATION COMME MTOR KINASE ET INHIBITEURS DE LA PI3 KINASE, ET LEURS SYNTHÈSES
申请人:WYETH LLC
公开号:WO2010030727A1
公开(公告)日:2010-03-18
The invention relates to 3-substituted-1H-indole, 3-substituted-1H-pyrrolo[2,3-b]pyridine, and 3-substituted-1H-pyrrolo[3,2-b]pyridine compounds of the Formula (I): or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.
3-SUBSTITUTED-1H-PYRROLO[2,3-B]PYRIDINE AND 3-SUBSTITUTED-1H-PYRROLO[3,2-B]PYRIDINE COMPOUNDS, THEIR USE AS MTOR KINASE AND PI3 KINASE INHIBITORS, AND THEIR SYNTHESES
申请人:Tsou Hwei-Ru
公开号:US20090298820A1
公开(公告)日:2009-12-03
The invention relates to 3-substituted-1H-pyrrolo[2,3-b]pyridine, and 3-substituted-1H-pyrrolo[3,2-b]pyridine compounds of the Formula 1:
or a pharmaceutically acceptable salt thereof, wherein the constituent variables are as defined herein, compositions comprising the compounds, and methods for making and using the compounds.
The liquid crystal properties of 3H-2-oxobenzofuran-6-yl 4-(n-CnH2n+1O)benzoates (1-n, n = 5–12), 4′-(n-CnH2n+1O)biphenyl-4-carboxylates (2-n, n = 6–10), and 4-(n-CnH2n+1)benzoates (3-n, n = 4–6) are described. The n = 5–8 homologues of 1-n exhibit a nematic (N) phase, and the n = 8–12 homologues exhibit a smectic A (SmA) phase, where the layer spacing is ca. 1.3 times of the calculated molecular length. The homologues of 2-n show a complex phase-transition behavior involving a smectic C (SmC), two kinds of SmA, reentrant nematic, and N phases, where the SmC phase is exhibited by the n = 6–8 homologues. The layer spacings of SmA phases formed at high and low temperature regions correspond to 1.3 and 1.0 times of the molecular lengths, respectively. The polar interactions around the terminal lactone moiety are assumed to play important roles for the complex polymesomorphism and diversity of the smectic layer structure.
3H-2-氧代苯并呋喃-6-基4-(n-CnH2n+1O)苯甲酸酯(1-n,n = 5–12)、4′-(n-CnH2n+1O)联苯-4-羧酸盐(2-n,n = 6–10)和4-(n-CnH2n+1)苯甲酸酯(3-n,n = 4–6)的液晶性质被描述。1-n 的 n = 5–8 homologues 展现出向列相(N),而 n = 8–12 的 homologues 则表现出 smectic A(SmA)相,其层间距约为计算分子长度的 1.3 倍。2-n 的 homologues 显示出复杂的相变行为,涉及 smectic C(SmC)、两种 SmA、回温向列相和 N 相,其中 n = 6–8 的 homologues 显示出 SmC 相。在高温和低温区域形成的 SmA 相的层间距分别对应于分子长度的 1.3 倍和 1.0 倍。假设端基内酯官能团周围的极性相互作用在复杂的多晶相变和层结构多样性中起着重要作用。
HAIR TREATMENT PRODUCTS COMPRISING POLYMERS
申请人:Schulze zur Wiesche Erik
公开号:US20090304620A1
公开(公告)日:2009-12-10
The invention relates to hair treatment products, comprising at least one copolymer made of 0.1 to 50% (in relation to the total number of monomers in the copolymer) monomers of the formula (I), wherein the unknowns are defined as in claim
1
, and A2) are monomers from the group of acrylic acid, methacrylic acid and the like, and—optionally non-ionic monomers from the group of acrylamide, vinyl alcohol, and the like, wherein the monomers A2 and A3 together represent 50 to 99.9% (in relation to the total number of monomers in the copolymer) of the copolymer, at least one silicon and at least one selected care product, wherein the products result in advantageous effects for skin and hair.
Substituted aurones were found to have antitrypanosomal, antifungal and immunomodulatory activity. The invention provides novel aurone compounds, pharmaceutical compositions, and methods encompassing medical and veterinary applications.